Tyroid nodule: not as clear-cut as it seems B enign etiologies and primary thyroid cancers are the most common causes of incidental thyroid nodules. Clinically evident metastases to the thyroid gland are not common and account for 2%-3% of thyroid cancers, though the incidence of thyroid metastases reaches 24% in autopsy studies.
of a positron-emission tomography scan reveal no extrathyroidal disease (Figure 1 ). We performed a fne-needle aspiration of the thyroid nodule. Te malignant cells displayed clear cytoplasm with oval nuclei and distinct nucleoli. Tey were positive for CD10, vimentin, EMA (epithelial membrane antigen), PNRA (proximal nephrogenic renal antigen), PAX2, PAX8, and CA9; and negative for TTF-1 (thyroid transcription factor-1; Figure 2 ). Diagnosis of metastatic clear-cell RCC to the thyroid gland was confrmed.
Te patient had good prognosis based on the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model: the interval from primary diagnosis to treatment >1 year (13 years for our patient); Karnofsky performance status >80% (100% denotes normal; 80%, normal activity with efort; some signs or symptoms of disease); a lactate dehydrogenase level <1.5 the upper limit of normal (109 U/L for our patient; normal: 140-280 U/L); corrected calcium level of less than the upper limit of normal (9.7 mg/dL; normal: 8.5-10.2 mg/dL) and a hemoglobin level of greater than or equal to lower limit of normal (13 g/dL; normal: 13.5-17.5 g/dL).
We decided to begin systemic therapy with sunitinib. After 3 months, the size of the nodule had decreased by more than 70%, with resolution of tumor grade activity. Subsequently, the patient underwent total thyroidectomy. Te surgical margins were focally positive for carcinoma. He then completed external beam radiation therapy to the thyroid bed. He is currently on long-term clinical and radiological surveillance.
Discussion
RCC accounts for about 4% of adult malignancies. 3 Te subtype is clear cell in 80% of cases. 4 It is a slow growing malignancy. Te median age at diagnosis is 66 years. 4 Te incidence of metastatic RCC is Vanderbilt University Medical Center, Division of Hematology-Oncology, Nashville, Tennessee increasing secondary to smoking and obesity. Metastases are present at diagnosis in 30%-40 % of cases, otherwise they are most likely to occur in the subsequent 3-5 years after initial diagnosis. Tey most commonly involve the lungs, lymph nodes, bones, liver, and brain. In the absolute majority of cases, they occur in more than 1 site. In metastatic RCC, overall 2-year survival rates in the favorable, intermediate, and poor risk categories are 45%, 17%, and 3%, respectively, based on history of nephrectomy, performance status, hemoglobin, lactate dehydrogenase, calcium, and albumin (MSKCC prognostic model). 5 In the era of targeted treatment, a newer risk prognostication model with the incorporation of platelet and neutrophil counts further validates MSKCC data. 6 Newer nomograms 7 incorporating molecular markers (Ki-67, endothelial VEGFR-1, p53, and so on) have shown more predictive accuracy for survival.
RCC is resistant to chemotherapy and partially respon- 11 Multifocality and positive surgical margins were associated with risk of contralateral recurrence. 8 In patients with a solitary kidney, even minimally invasive surgery may lead to renal failure. RFA must be attempted frst, especially for exophytic masses that are <3 cm in diameter. 9 For large tumors or tumors adjacent to critical structures, combined embolization must be performed. It is interesting to note that patients with metachronous contralateral tumors are at a higher risk of developing distant metastases.
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FIGURE 1
Positron-emission tomography images before (A) and after (B) therapy. Metastases to the thyroid gland are not common. Tat may be explained by the thyroid rapid arterial fow, which prevents adhesion of tumor emboli, 11 and by the high content of oxygen and iodine, which inhibit malignant growth. Tus, any thyroid pathology can predispose to metastatic growth by alteration of the thyroid microenvironment. 12 Clear-cell cytology is not limited to clear-cell RCC. A tumor-directed immunohistochemistry is crucial for diagnosis. If the fne-needle ablation results are inconclusive, then thyroidectomy must be performed. 1 For solitary metastases that may be surgically resectable, metastasectomy with or without a short course of neoadjuvant VEGF-targeted therapy or tyrosine kinase inhibitor is the mainstay of treatment. Surgery is thought to be the only intervention with cure potential, provided that the disease is limited to the thyroid gland. 13 In the case series from Mayo Clinic, 14 survival rates at 1, 3, and 5 years after metastasectomy were 77%, 59%, and 31%, respectively. Data from MD Anderson Cancer Center, Houston, Texas, showed an overall survival of 5 years in 29% of patients in a group that underwent metastasectomy for solitary lesions, 15 compared with <20% in untreated patients. Surgery is considered palliative if the surgical margins are tumor infltrated. Radiation therapy may be considered in cases of incomplete metastases removal or local recurrence. Factors afecting survival after thyroidectomy include positive surgical margins, being younger than 70 years, metastases in the contralateral kidney during disease course, and presence of more than 4 thyroid metastases. Median survival after thyroid metastasectomy is 2 years (Table) .
In conclusion, thyroid metastases must be included in the diferential diagnosis of thyroid nodule, especially in patients with a history of cancer, even decades after initial diagnosis. Tus, we suggest an expedited pathological diagnosis of occult thyroid nodule in individuals with history of RCC. 
